Deciphera Pharmaceuticals LLC (DCPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Deciphera Pharmaceuticals LLC stock (DCPH) is currently trading at $25.59. Deciphera Pharmaceuticals LLC PS ratio (Price-to-Sales) is 12.65. Analyst consensus price target for DCPH is $27.52. WallStSmart rates DCPH as Sell.
- DCPH PE ratio analysis and historical PE chart
- DCPH PS ratio (Price-to-Sales) history and trend
- DCPH intrinsic value — DCF, Graham Number, EPV models
- DCPH stock price prediction 2025 2026 2027 2028 2029 2030
- DCPH fair value vs current price
- DCPH insider transactions and insider buying
- Is DCPH undervalued or overvalued?
- Deciphera Pharmaceuticals LLC financial analysis — revenue, earnings, cash flow
- DCPH Piotroski F-Score and Altman Z-Score
- DCPH analyst price target and Smart Rating
Deciphera Pharmaceuticals LLC
📊 No data available
Try selecting a different time range
Smart Analysis
Deciphera Pharmaceuticals LLC (DCPH) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Deciphera Pharmaceuticals LLC (DCPH) Key Strengths (3)
Revenue surging 34.50% year-over-year
72.03% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Deciphera Pharmaceuticals LLC (DCPH) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 12.7x annual revenue
Very expensive at 7.0x book value
Supporting Valuation Data
Deciphera Pharmaceuticals LLC (DCPH) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 34.50%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (12.65), Price/Book (7.00) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -50.40%, Operating Margin at -108.50%, Profit Margin at -108.90%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -50.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 34.50% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
DCPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
DCPH's Price-to-Sales ratio of 12.65x trades at a deep discount to its historical average of 53.93x (39th percentile). The current valuation is 94% below its historical high of 216.64x set in Jan 2020, and 93% above its historical low of 6.55x in Oct 2023.
Compare DCPH with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Deciphera Pharmaceuticals LLC (DCPH) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Deciphera Pharmaceuticals LLC is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 175M with 35% growth year-over-year. The company is currently unprofitable, posting a -108.9% profit margin.
Key Findings
Revenue growing at 35% YoY, reaching 175M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Spending 33% of revenue (57M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -108.9% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -55M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Deciphera Pharmaceuticals LLC maintain 35%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Deciphera Pharmaceuticals LLC.
Bottom Line
Deciphera Pharmaceuticals LLC is a high-conviction growth story with revenue accelerating at 35% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -108.9% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:06:44 AM
About Deciphera Pharmaceuticals LLC(DCPH)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to improve the lives of cancer patients by addressing key drug resistance mechanisms that limit the rate and durability of response to existing cancer therapies. The company is headquartered in Waltham, Massachusetts.